A new case report was published in Oncoscience's Volume 12 on March 31, 2025, titled "Cystadenofibroma and contralateral ...

Explore GISTs, rare GI tumors. Discover key details on genetic causes, diagnostic methods, and cutting-edge treatment ...

These particles can be targeted directly to tumors ... to serve as markers on the cancer cells that activate the immune system locally in the tumor. In mouse models of ovarian cancer, this ...

These particles can be targeted directly to tumors, where they release their payload while ... This allows the nanoparticles to serve as markers on the cancer cells that activate the immune system ...

For a long time, scientists thought this cancer came from the ovaries. But this new research, led by Professor Alexander ...

We have examined various clinical and histopathological (microscopic) markers in both primary tumors and lymph node metastases in patients. The analyses show that these markers can distinguish ...

Ovarian cancer is a relatively manageable malignancy ... several groups have pioneered the task in determining HE4's efficacy as a molecular marker for OC. Although HE4 has consistently shown ...

Additionally, it increased expression of the autophagy-related marker LC3B-II and cell death as marked by cleaved caspase-3 ... Understanding the heterogeneity of FOLR1 expression in ovarian tumors is ...

Search for other works by this author on: ...

If you have ovarian cancer, your outcomes will be better if you are treated by a gynecologic oncologist right from the beginning. Fred Hutch Cancer Center has more gynecologic oncologists than any ...